opioids
pain
IASP defines pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage
pain threshold
the point at which that stimulus is experienced as pain
differs from person to person
pain tolerance
the duration of time or the intensity of pain that a person will endure before taking over action to relieve the pain
decreases with repeated exposure to pain
decreased by fatigue, anger, fear, and sleep deprivation
physical dependence
abstinence syndrome with abrupt discontinuation
about 10 hours after last dose: initial reaction is yawning, rhinorrhea, sweating
progresses to: sneezing, weakness, nausea, vomiting, diarrhea, abdominal cramps, bone and muscle pain, muscle spasm, kicking movements
lasts 7-10 days if untreated
withdrawal unpleasant but not lethal, as is possible with CNS depressants
NOT equated with addiction
Addiction
behavior pattern characterized by continued use of a psychoactive substance despite physical, psychologic, or social harm
addicts will do anything to get their high
acute pain
less than 6 months
acute somatic, acute visceral, referred pain
acute somatic
arises from connective tissue, muscle, bone and skin
sharp and localized or dull and non-localized
responds best to:
acetaminophen, corticosteroids, NSAIDS, opiates, local anesthetics, ice, massage
acute visceral
pain in the internal organs and abdomen
poorly localized
radiates
most responsive to opiates
may also use: corticosteroids and NSAIDS
referred pain
pain that is present in an area removed or distant from its point of origin
analgesics
drugs that relieve pain without causing loss of consciousness
drugs for acute pain
morphine and other opioid agonists
centrally acting non-narcotic analgesic: acetaminophen
COX inhibitors: NSAIDS, salicylates, COX-2 inhibitors
Drugs for moderate to severe pain
morphine and opiates
oral forms vs IV vs transdermal
moderate pain use: codeine or codeine/acetaminophen, hydrocodone or hydrocodone/acetaminophen
severe pain: morphine, oxycodone
chronic pain
usually defined as lasting at least 3-6 months
response patterns vary
produces significant behavior and psychological changes
common types of chronic pain:
central pain
non-neuropathic pain
neuropathic pain
psychogenic pain
central chronic pain
CNS lesions or dysfunction
mirgraines
treatment: treat cause, medications
non-neuropathic pain
myofascial pain syndromes:
fibromyalgia
myositis
myalgia
muscle strain
drug choices:
NSAIDS
TCAs
serotonin reuptake inhibitors
neuropathic pain
result of trauma or disease of nerves
most often chronic
diabetic neuropathy
postherpetic neuralgia
deafferentation pain
sympathetically maintained pain
complex regional pain syndromes (CRPS)
central pain
phantom limb pain
(burning and tingling sensation)
drugs for neuropathic pain
anti-epileptics
pregabalin
gabapentin
antidepressants
TCAs
serotonin and norepinephrine reuptake inhibitor
duloxetine (cymbalta)
management strategy
ask about pain regularly
believe the patient and family in their reports of pain and what relieves it
choose pain control options appropriate for the patient, family, and setting
deliver interventions in a timely, logical, coordinated fashion
empower patients and their families
opioid
a general term defined as any drug, natural or synthetic, that has actions similar to those of morphine
endogenous opioid peptides
three families of peptides
enkephalins
endorphins
dynorphins
found in the CNS and peripheral tissues
we know that these peptides serve as neurotransmitters, neurohormones, and neuromodulators, the precise physiological role is not understood
basic pharmacology of the opioids
strong opioid agonists
morphine
other strong opioid agonists
moderate to strong opioid agonists
agonist-antagonist opioids
morphine
therapeutic use: relief of pain
mechanism of analgesic action
moderate to severe pain
preoperative treatment of anxiety
adverse effects of morphine
respiratory depression
onset: IV 7 min, IM 30 min, subQ up to 90 min, may persist 4-5 hrs
tolerance to respiratory depression with concurrent use of other drugs that have CNS depressant actions (eg. alcohol, barbiturates, etc.)
can compromise patients with impaired pulmonary function: asthma, emphysema, kyphoscoliosis, chronic cor pulmonale
constipation
orthostatic hypotension
cough suppression
emesis
urinary retention
euphoria/dysphoria
sedation
miosis
intracranial pressure (ICP)
birth defects
pharmacokinetics of morphine
administered by several routes: PO, IM, IV, subQ, epidural, and intrathecal
not very lipid-soluble
does not cross blood-brain barrier easily
only small fraction of each dose reaches site of analgesic action
precautions: decreased respiratory reserve, pregnancy, labor and delivery, head injury
morphine toxicity, treatment, general guidelines, dosage, and administration
clinical manifestations
classic triad: coma, respiratory depression, pinpoint pupils
treatment: ventilatory support, antagonist: naloxone (Narcan)
general guidelines: monitor full vitals before giving, give on a fixed schedule
dosage and routes of administration: oral, intramuscular and subcutaneous, intravenous, epidural and intrathecal
fentanyl
(sublimaze, duragesic, abstral, actiq, fentora, onsolis)
100 times the potency of morphine
five formulations in three routes
parenteral (sublimaze)
surgical anesthesia
transdermal (duragesic)
patch - heat acceleration
iontophoretic system - needle-free
transmucosal
lonzenge on a stick (actiq)
buccal film (onsolis)
buccal tablets (fentora)
sublingual tablets (abstral)
meperidine
short half-life
interacts adversely with several other drugs
toxic metabolite accumulation
recommend to avoid
methadone
treatment for pain and opioid addicts
hydromorphone (dilaudid)
much more potent than morphine
less nausea than morphine
1.5 mg of hydromorphone IV= 10 mg of morphine IV
refer to page 268 for equianalgesic dosing
moderate to strong opioid agonists
similar to morphine in most respects
produce analgesia, sedation, euphoria
can cause: respiratory depression, constipation, urinary retention, cough suppression, and miosis
can be reversed with naloxone
different from morphine
produce less analgesia and respiratory depression than morphine
somewhat lower potential for abuse
codeine
actions and uses
10% converts to morphine in liver
pain and cough suppression
preparations, dosage, and administration
usually oral
30 mg produces same effect as 325 mg acetaminophen
oxycodone
analgesic actions equivalent to those of codeine
long-acting analgesic
immediate-release
controlled-release (OxyCotin)
abuse: crushes and snorts or injects medication
hydrocodone
most widely prescribed drug in the United States
combined with aspirin, acetaminophen, or ibuprofen
same side effects as other opioids
agonist-antagonist opioids
Pentazocine - Talwin
Nalbuphine - Nubain
Butorphanol-Stadol
Buprenorphine
7-day patch: Butrans
Sublingual film: Suboxone
clinical use of opioids
pain assessment
essential component of management
based on patient’s description
Evaluate:
pain location, characteristics, and duration; things that improve/worsen pain
status before drug and 1 hour after
balance the need to provide pain relief with the desire to minimize abuse
patient-controlled analgesia
PCA devices
drug selection and dosage regulations
comparison of PCA with traditional intramuscular therapy
patient education
dosing guidelines
assessment of pain
dosage determination
(no ceiling dose for pure opioids)
dosing schedule
avoiding withdrawal
opioid antagonists
drugs that block the effects of opioid agonists
principal uses:
treatment of opioid overdose, relief of opioid-induced constipation
reversal of postoperative opioid effects
management of opioid addiction
agonist binds to MU receptor
analgesia
respiratory depression
euphoria
sedation
decreased GI motility
physical dependence
(most important for pain relief)
agonist-antagonist opioids binding to Kappa
analgesia (not as strong)
sedation
decreased GI motility
patient-controlled analgesia
PCA devices
drug selection and dosage regulations
comparison of PCA with traditional intramuscular therapy
patient education
opioid antagonists
drugs that block the effects of opioid agonists
principal uses:
treatment of opioid overdose, relief of opioid induced constipation
reversal of postoperative opioid effects
management of opioid addiction
pure opioid antagonists
naloxone (narcan)
other pure opioid antagonists:
methylnaltrexone (relistor)
alvimopan (entereg)
naltrexone (revia, vivitrol)
naloxone
therapeutic uses
reversal of opioid overdose
drug of choice with pure opioid agonist overdose
titrated cautiously with physical dependence
reversal of postoperative opioid effects
titrated to achieve adequate ventilation and to maintain pain relief
reversal of neonatal respiratory depression
opioids given during labor and delivery may cause respiratory depression in neonate
methylnaltrexone
selective opioid antagonist
treatment of opioid-induced constipation in late-stage disease for patients on constant opioids
nonopioid centrally acting analgesics
relieve pain by mechanisms largely or completely unrelated to opioid receptors
do not cause respiratory depression, physical dependence, or abuse
not regulated under the Controlled Substances Act
ex: tramadol, clonidine (duraclon), ziconotide (prialt), dexmedetomidine (precedex)
tramadol
mechanism of action
combination of opioid and nonopioid mechanisms
drug interactions
CNS depressants
abuse liability - IV (schedule)
preparations, dosage, and administration
immediate-release and extended-release
clonidine
mechanisms of pain relief
alpha 2-adrenergic agonist
analgesic use
used in combination with opioid analgesic
adverse effects
cardiovascular: severe hypotension, rebound hypertension, bradycardia